EXECUTIVE EMPLOYMENT AGREEMENT


 


THIS EXECUTIVE
EMPLOYMENT AGREEMENT (“Agreement”) is dated as of July 2, 2012 (the “Effective Date”)
and is entered into by and between Adamis Pharmaceuticals Corporation, a Delaware corporation (“Company”),
and Thomas H. Moll, Ph.D. (“Executive”).


 


BACKGROUND


 


A.             Executive
is currently employed by the Company as its Vice President of Research.


 


B.             The
Company and Executive desire to formally state the terms and conditions of Executive’s employment by the Company and to provide
Executive with certain benefits upon a qualifying termination of such employment.


 


C.             The
Company desires to employ Executive in the executive capacity hereinafter stated, and the Executive desires to be employed by the
Company in such capacity for the period and with the terms and conditions set forth herein.


 


AGREEMENT


 


NOW, THEREFORE,
in consideration of the promises and the covenants set forth in this Agreement and for other valuable consideration, the parties
hereby agree as follows:


 


1.             Employment.
The Company hereby employs Executive as Vice President of Research, assigned with responsibilities to do and perform all services,
acts, or things necessary or advisable to manage and conduct the business of the Company, subject at all times to the policies
set by the Board of Directors of the Company (the “Board”), and to the consent of the Board when required by
the terms of this contract. Executive hereby accepts such employment and agrees to devote such time and energies as appropriate
to fulfill all responsibilities to the Company. Executive shall be employed at will.


 


2.             Compensation.
In consideration for all services rendered by Executive under this Agreement, Executive shall receive the compensation described
in this Section 2. All such compensation shall be paid subject to appropriate tax withholding and similar deductions.


 


(a)           Salary.
Executive shall be paid an initial annual salary of $225,000, payable in accordance with the Company’s normal practices
in the payment of salary and wages practices, in equal installments, but not less than 24 increments annually.


 


(b)           Executive
Benefit and Incentive Compensation Plans. During employment hereunder, Executive shall be entitled to receive those benefits
which are routinely made available to executive officers of the Company, including participation in any executive stock ownership
plan, profit sharing plan, incentive compensation or bonus plan, retirement plan, Company-provided life insurance, or similar
executive benefit plans maintained or sponsored by the Company. The Company shall not take any action that would materially diminish
the aggregate value of Executive’s fringe benefits as they exist as of the Effective Date of this Agreement or as the
same may be increased from time to time, except for actions taken with respect to officers or employees generally.


 



    	1



    	 



    
 





(c)           Expense
Reimbursement. The Company shall promptly reimburse Executive for all reasonable expenses necessarily incurred during conduct
of Company business, and for which adequate documentation is presented, but in no event later than December 31 of the year
following the year in which the expense was incurred.


 


(d)           Personal Time
Off. Executive shall be entitled to paid time off in accordance with the Company’s policies applicable to executives.


 


3.             Termination.
Executive’s employment may be terminated as follows, with the following effects:


 


(a)           Death. Executive’s
employment shall terminate immediately upon the Executive’s death, in which event the Company’s only obligations hereunder
shall be to pay all compensation and expense reimbursements owing for services rendered and reasonable business expenses incurred
by the Executive prior to the date of his death. If Executive’s employment ceases as a result of death, then all unvested
options to purchase Common Stock of the Company held by Executive shall immediately terminate and become unexercisable and all
vested options held by Executive shall remain exercisable until the one year anniversary of the date of cessation of service.


 


(b)           Disability.
In the event the Executive is disabled from performing his assigned duties under this agreement due to illness or injury for
a period in excess of sixty (60) consecutive days or a period or periods of more than one hundred and twenty (120) days
in the aggregate in any twelve month period, the Board, in its sole discretion, may terminate Executive’s employment immediately
upon written notice to Executive, in which event the Company’s only obligations hereunder shall be to pay all compensation
and expense reimbursements owing for services rendered and reasonable business expenses incurred by the Executive prior to the
effective date of termination. If Executive’s employment ceases as a result of disability, then all unvested options to
purchase Common Stock of the Company held by Executive shall immediately terminate and become unexercisable and all vested options
held by Executive shall remain exercisable until the one year anniversary of the date of cessation of service.


 


(c)           For Cause.
The Company may terminate Executive’s employment for Cause immediately upon written notice from the Board to Executive.
For purposes of this Agreement, “Cause” means the occurrence of any one or more of the following: (i) Executive’s
conviction of or plea of nolo contendere to any felony crime involving fraud, dishonesty or moral turpitude under the laws of
the United States or any state thereof; (ii) Executive’s attempted commission of, or participation in, a fraud or act
of dishonesty against the Company; (iii) Executive’s intentional, material violation of any contract or agreement between
the Participant and the Company or of any statutory duty owed to the Company; (iv) Executive’s unauthorized use or
disclosure of the Company’s confidential information or trade secrets; or (v) Executive’s gross misconduct. In
the event Executive’s employment is terminated for Cause, the Company shall have no further obligations to Executive other
than to pay all compensation and expense reimbursements owing for services rendered and reasonable business expenses incurred
by Executive prior to the effective date of such termination.


 



    	2



    	 



    
 





(d)           Without Cause.
The Company in its sole discretion may terminate Executive’s employment without Cause (as defined above) or prior warning
immediately upon written notice from the Board to Executive, in which event, the Company shall pay to Executive all compensation
and expense reimbursements owing for services rendered and reasonable business expenses incurred by Executive prior to the effective
date of termination, and provided such termination is a “separation from service” as such term is defined in Section 409A(a)(2)(A)(i)
of the Internal Revenue Code of 1986, as amended (the “Code”) and the applicable guidance thereunder,
contingent upon Executive’s delivery to the Company of an effective Release and Waiver as provided in Section 3(e)
below, the Company shall also provide the following benefits to Executive: (i) severance consisting of continued payment
of Executive’s base salary at the rate in effect as of the effective date of termination, less standard deductions and withholdings,
for a period of nine (9) months following the effective date of termination, subject to acceleration of such payments into
a single lump-sum cash severance payment in the event a Change in Control (as defined below, provided that the Change in Control
is an event described in Code Section 409A(a)(2)(A)(v)) of the Company has occurred prior to the date of termination (but
not more than two years prior to such termination) or a Change in Control occurs within ninety (90) days after the date of
termination of Executive’s employment, provided that any such acceleration complies with the provisions of Code Section 409A(a)(3);
(ii) to the extent that Executive is eligible to continue medical benefits under COBRA and upon timely election by Executive
complying with COBRA, payment of all premiums required to continue Executive’s medical, dental and vision insurance coverage
to the extent permitted by COBRA for a period of nine (9) months following the date of termination (with Executive being
responsible to pay that amount of the portion of the premiums, if any, that Executive would have been responsible to pay if Executive
had remained an employee during such period) or, if earlier, the date that Executive accepts full time employment with another
employer; and (iii) immediate acceleration of the vesting of all options to purchase the common stock of the Company granted
to Executive prior to the effective date of such termination (the “Options”) such that Executive shall
be deemed vested as to the same number of shares as if Executive had continued to be employed by the Company for a period of nine
(9) months following the effective date of such termination (subject to the additional accelerated vesting provided in Section 4(b)
in the event Executive is terminated by the Company without Cause within 90 days prior to or within 13 months following the effective
date of a Change in Control) and all vested options held by Executive shall remain exercisable until the one year anniversary
of the date of cessation of service. As a condition to receiving the continuing benefits specified in this Section 3(d),
to the maximum extent permitted by applicable law, during the nine (9) month period following the Executive’s termination
date, Executive shall not engage in any employment or business activity that is directly competitive with the Company’s
business activities as of such termination date and Executive shall not induce any employee of the Company to leave the employ
of the Company.


 



    	3



    	 



    

 


(e)           Release and
Waiver. As a condition to receiving the benefits specified in Sections 3(d) and 4(b) of this Agreement, Executive must deliver
to the Company a fully effective waiver and release of claims in the form attached hereto as Exhibit A (the “Release
and Waiver”) within the time frame set forth therein, but in no event later than forty-five (45) days following
the Executive’s termination date. The Company may withhold payment of the severance compensation described in paragraph
(d) above until Executive executes and delivers the Release and Waiver.


 


(f)           Voluntary Termination
by Executive. Executive may terminate his employment hereunder at any time, whether with or without cause, effective thirty
(30) days after delivery of written notice of such termination to the Company, except for Executive’s Emergency Need.
“Emergency Need”, as used in this Section, is defined to be the advent of illness or related health
issues in Executive or his immediate family which a medical doctor would conclude poses a mortal health risk to that person. The
Company shall have the option, in its sole discretion, to specify an earlier termination date than that provided by Executive
in the written notice. Upon voluntary termination pursuant to this Section, the Company shall have no further obligations to Executive
other than to pay all compensation and expense reimbursements owing for services rendered and reasonable business expenses incurred
by Executive prior to effective date of termination as determined by the Company. If Executive voluntarily terminates his employment,
then all unvested options to purchase Common Stock of the Company held by Executive shall immediately terminate and become unexercisable
and all vested options held by Executive shall remain exercisable for six (6) months from the date of the voluntary termination.


 


(g)           Resignation
as a Director. In the event of any termination of employment pursuant to this Agreement, Executive shall be deemed to have
resigned voluntarily from the Board and any Committee of the Board, and of the board of directors (and any committee thereof)
of all subsidiaries of the Company, upon the effective date of termination or such earlier date as may be agreed in writing between
the Company and Executive, and Executive’s signature on this Agreement shall, without the need to any further action, constitute
Executive’s resignation from such boards of directors in such circumstance.


 


(h)           Returning Company
Documents. In the event of any termination of Executive’s employment hereunder, Executive shall, prior to or on such
termination deliver to the Company (and will not maintain possession of or deliver to anyone else) any and all devices, records,
data, data bases software, software documentation, laboratory notebooks, notes, reports, proposals, lists, customer lists, correspondence,
specifications, drawings, blueprints, sketches, materials, equipment, other documents or property, or reproductions of any of
the above aforementioned items belonging to the Company, its successors or assigns.


 


4.             Change in
Control.


 


(a)           Option Acceleration
Upon a Change in Control. Effective immediately upon the closing of a Change in Control of the Company, the vesting of all
of the then unvested shares of Common Stock subject to the Options shall be accelerated in full and the Options shall become fully
vested and immediately exercisable as to such additional vested shares (and, if any Options have been early exercised by Executive,
the reacquisition or repurchase rights held by the Company with respect to the shares of Common Stock subject to such acceleration
shall lapse in full, as appropriate).


 



    	4



    	 



    
 


(b)           Benefits Upon
Termination. In the event that Executive’s employment by the Company is terminated without Cause (as defined above)
or Executive terminates his employment for Good Reason (as defined below), in each case within ninety (90) days prior to
or within thirteen (13) months following the effective date of a Change in Control (as defined below) of the Company, contingent
upon Executive’s delivery to the Company of a fully effective Release and Waiver as provided in Section 3(e) and provided
such termination is a “separation from service” as such term is defined in Code Section 409A(a)(2)(A)(i), the
Executive shall be entitled to the benefits and payments specified in Sections 3(d)(i) and 3(d)(ii) above, and the vesting of
the unvested shares of Common Stock subject to the Options shall immediately accelerate in full such that the Options shall become
fully vested and exercisable with respect to all of the shares of Common Stock subject to such Options (and, if any Options have
been early exercised by Executive, the reacquisition or repurchase rights held by the Company with respect to the shares of Common
Stock subject to such acceleration shall lapse in full, as appropriate).


 


(c)           Change
in Control. “Change in Control” means the occurrence, in a single transaction or in a series of
related transactions, of any one or more of the following events:


 


(i)          any Exchange
Act Person (as defined below) becomes the beneficial owner, directly or indirectly, of securities of the Company representing
more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities other than
by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed
to occur (A) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other
Exchange Act Person from the Company in a transaction or series of related transactions the primary purpose of which is to obtain
financing for the Company through the issuance of equity securities or (B) solely because the level of beneficial ownership
held by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage threshold of
the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing
the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as
a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes
the beneficial owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred,
increases the percentage of the then outstanding voting securities beneficially owned by the Subject Person over the designated
percentage threshold, then a Change in Control shall be deemed to occur (for purposes of this Section 4(c), “Exchange
Act Person” means any natural person, entity or “group” (within the meaning of Section 13(d) or
14(d) of the Securities Exchange Act of 1934, as amended (“Exchange Act”)), except that “Exchange
Act Person” shall not include (A) the Company or any subsidiary of the Company, (B) any employee benefit plan
of the Company or any subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit
plan of the Company or any subsidiary of the Company, (C) an underwriter temporarily holding securities pursuant to an offering
of such securities, (D) an entity beneficially owned, directly or indirectly, by the stockholders of the Company in substantially
the same proportions as their beneficial ownership of stock of the Company; or (E) any natural person, entity or “group”
(within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the date of this Agreement, is the beneficial
owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting
power of the Company’s then outstanding securities);


 



    	5



    	 



    
 


 (ii)          there
is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately
after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior
thereto do not beneficially own, directly or indirectly, either (A) outstanding voting securities representing more than
fifty percent (50%) of the combined outstanding voting power of the surviving entity in such merger, consolidation or similar
transaction or (B) more than fifty percent (50%) of the combined outstanding voting power of the parent of the surviving
entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions relative to each
other as their beneficial ownership of the outstanding voting securities of the Company immediately prior to such transaction;


 


(iii)          the stockholders
of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete dissolution
or liquidation of the Company shall otherwise occur, except for a liquidation into a parent corporation;


 


(iv)          there is consummated
a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and
its subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets
of the Company and its subsidiaries to an entity, more than fifty percent (50%) of the combined voting power of the voting
securities of which are beneficially owned by stockholders of the Company in substantially the same proportions relative to each
other as their beneficial ownership of the outstanding voting securities of the Company immediately prior to such sale, lease,
license or other disposition; or


 


(v)          individuals
who, on the date of this Agreement, are members of the Board (the “Incumbent Board”) cease for any reason
to constitute at least a majority of the members of the Board; (provided, however, that if the appointment or election
(or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent
Board then still in office, such new member shall, for purposes of the Plan, be considered as a member of the Incumbent Board).


 


(d)           Good Reason.
“Good Reason” for the Executive to terminate the Executive’s employment hereunder shall mean the occurrence
of any of the following events without the Executive’s consent:


 


(i)          a material adverse
change in the nature of the Executive’s authority, duties or responsibilities, as they exist on the Effective Date of this
Agreement;


 


(ii)          the relocation
of the Company’s executive offices or principal business location to a point more than sixty (60) miles from their
location as of the Effective Date of this Agreement; or


 


(iii)          a material
reduction by the Company of the Executive’s base salary as initially set forth herein or as the same may be increased from
time to time, except for across-the-board salary reductions based on the Company’s financial performance similarly affecting
all or substantially all senior officers of the Company and does not exceed 15% of Executive’s base salary.


 



    	6



    	 



    
 


Provided however that,
such termination by the Executive shall only be deemed for Good Reason pursuant to the foregoing definition if: (i) the Executive
gives the Company written notice of the intent to terminate for Good Reason within thirty (30) days following the first occurrence
of the condition(s) that the Executive believes constitutes Good Reason, which notice shall describe such condition(s); (ii) the
Company fails to remedy such condition(s) within thirty (30) days following receipt of the written notice (the “Cure
Period”); and (iii) the Executive terminates employment within thirty (30) days following the end of the
Cure Period.


 


5.             Application
of Internal Revenue Code Section 409A. Benefits payable under the Agreement, to the extent of payments made from the
date of termination of the Executive through March 15th of the calendar year following such termination, are intended to
constitute separate payments for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations and thus payable pursuant
to the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations; to the extent
such payments are made following said March 15th, they are subject to the distribution requirements of Code Section 409A(a)(2)(A),
including, without limitation, the requirement of Code Section 409A(a)(2)(B)(i) that payment to the Executive be delayed
until 6 months after separation from service if the Executive is a “specified Executive” within the meaning of the
aforesaid section of the Code at the time of such separation from service. In addition, if any provision of this Agreement would
cause Executive to incur any penalty tax or interest under Section 409A of the Code or any regulations or Treasury guidance promulgated
thereunder, the Company may reform such provision to maintain to the maximum extent practicable the original intent of the applicable
provision without violating the provisions of Section 409A of the Code.


 


6.             Code Section 280G.
If any payment or benefit Executive would receive pursuant to a Corporate Transaction from the Company or otherwise (“Payment”)
would (i) constitute a “parachute payment” within the meaning of Code Section 280G, and (ii) but for
this sentence, be subject to the excise tax imposed by Code Section 4999 (the “Excise Tax”), then
the Company shall cause to be determined, before any amounts of the Payment are paid to Executive, which of the following two
amounts would maximize Executive’s after-tax proceeds: (i) payment in full of the entire amount of the Payment (a “Full
Payment”), or (ii) payment of only a part of the Payment so that Executive receives the largest payment possible
without the imposition of the Excise Tax (a “Reduced Payment”), whichever amount results in Executive’s
receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may
be subject to the Excise Tax. For purposes of determining whether to make a Full Payment or a Reduced Payment, the Company shall
cause to be taken into account all applicable federal, state and local income and employment taxes and the Excise Tax (all computed
at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction
of such state and local taxes). If a Reduced Payment is made, (i) the Payment shall be paid only to the extent permitted
under the Reduced Payment alternative, and Executive shall have no rights to any additional payments and/or benefits constituting
the Payment, and (ii) reduction in payments and/or benefits shall occur in the following order: reduction of cash payments,
cancellation of accelerated vesting of stock awards, and reduction of other benefits. In the event that acceleration of compensation
from Executive’s equity awards is to be reduced, such acceleration of vesting shall be canceled in the reverse order of
the date of grant unless Executive elects in writing a different order for cancellation.


 



    	7



    	 



    
 


The independent
registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of
the Corporate Transaction shall make all determinations required to be made under this Section 6. If the independent registered
public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting
the Corporate Transaction, the Company shall appoint a different nationally recognized independent registered public accounting
firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such
independent registered public accounting firm required to be made hereunder. The independent registered public accounting firm
engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to
the Company and Executive within fifteen (15) calendar days after the date on which Executive’s right to a Payment is
triggered (if requested at that time by the Company or Executive) or at such other time as requested by the Company. If the independent
registered public accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the
application of the Reduced Amount, it shall furnish the Company and Executive with an opinion reasonably acceptable to Executive
that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder
shall be final, binding and conclusive upon the Company and Executive.


 


7.             Conflict of
Interest. During the Employment Period, Executive shall devote such time and energies as appropriate to fulfill all responsibilities
to the Company in the capacity set forth in Section 1. Executive shall be free to pursue business activities which do not
interfere with the performance of his duties and responsibilities under this Agreement, however, Executive shall not engage in
any outside business activity which involves actual or potential competition with the business of the Company, except with the
written consent of the Board.


 


8.             Executive
Benefit Plans. All of the Executive benefit plans referred to or contemplated by this Agreement shall be governed solely by
the terms of the underlying plan documents and applicable law. Nothing in this Agreement shall impair the Company’s right
to amend, modify, replace, and terminate any and all such plans in its sole discretion as provided by law. This Agreement is for
the sole benefit of Executive and the Company, and is not intended to create an Executive benefit plan or to modify existing terms
of existing plans.


 


9.             Assignment.
This Agreement may not be assigned by Executive. This Agreement shall bind and inure to the benefit of the Company’s
successors and assigns, as well as Executive’s heirs, executors, administrators, and legal representatives. The Company
shall obtain from any successor, before the succession takes place, an agreement to assume the obligations and perform all of
the terms and conditions of this Agreement.


 


10.             Notices.
All notices required by this Agreement may be delivered by first class mail at the following addresses:


 


To Company:


 



    	8



    	 



    
 


	 	Adamis Pharmaceuticals Corporation
	 	Attn: Board of Directors
	 	11455 El Camino Real, Suite 310
	 	San Diego, CA 92130
	 	 
	 	To Executive:
	 	 
	 	Thomas H. Moll, Ph.D.



	 	 	 	 	 



	 	 	, CA 92	 	 	 	 



 


11.             Amendment.
This Agreement may be modified only by written agreement signed by both the Company and Executive.


 


12.             Choice of
Law; Arbitration. This Agreement shall be governed by the laws of the State of California, without regard to choice of law
principles. To provide a mechanism for rapid and economical dispute resolution, Executive and the Company agree that any and all
disputes, claims, or causes of action, in law or in equity, arising from or relating to this Agreement (including the Release
and Waiver) and its enforcement, performance, breach or interpretation, will be resolved, to the fullest extent permitted by law,
by final, binding and confidential arbitration before a single arbitrator held in San Diego, California and conducted by the American
Arbitration Association (“AAA”), under its then-existing rules and procedures. The parties shall be
entitled to conduct adequate discovery, and they may obtain all remedies available to the parties as if the matter had been tried
in court. The arbitrator shall issue a written decision which specifies the findings of fact and conclusions of law on which the
arbitrator’s decision is based. Judgment upon the award rendered by the arbitrator may be entered by any court having jurisdiction
thereof. Unless a different allocation is required by law, the parties shall each pay one-half of all fees and costs of the arbitration.
Punitive damages shall not be awarded. Unless otherwise required by law, the arbitrator will award reasonable expenses (including
reimbursement of the assigned arbitration costs) to the prevailing party. Nothing in this Section or in this Agreement is intended
to prevent either Executive or the Company from obtaining injunctive relief in a court of competent jurisdiction to prevent irreparable
harm pending the conclusion of any such arbitration. Notwithstanding the above, both Executive and the Company retain the
right to seek or obtain, and shall not be prohibited, limited or in any other way restricted from seeking or obtaining, equitable
relief from a court having jurisdiction over the parties in order to enforce the nonsolicitation and noncompetition provisions
of this Agreement or any disputes or claims relating to or arising out of the misuse or misappropriation of the Company’s
intellectual property.


 


13.             Partial Invalidity.
In the event any provision of this Agreement is void or unenforceable, the remaining provisions shall continue in full force
and effect.


 


14.             Waiver.No
waiver of any breach of this Agreement shall constitute a waiver of any subsequent breach.


 


15.             Complete
Agreement. As of the Effective Date, this Agreement, together with the stock option agreements and equity incentive plans
governing the Options, constitutes the entire agreement between the parties in connection with the subject matter hereof and supersedes
any and all prior or contemporaneous oral and written agreements or understandings between the parties.


 



    	9



    	 



    
 


16.             Headings.
Headings in this Agreement are included herein for convenience of reference only and shall not constitute a part of this Agreement
for any other purpose.


 


17.             Miscellaneous.
Executive acknowledges full understanding of the matters set forth herein and the obligations undertaken upon the execution
hereof.


 


[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK]


 



    	10



    	 



    
 


IN WITNESS WHEREOF,
the parties have executed this EXECUTIVE EMPLOYMENT AGREEMENT as of the date first written above.


 


ADAMIS PHARMACEUTICALS CORPORATION


 


	By:	/s/ Dennis J. Carlo	 
	Name:	Dennis J. Carlo	 
	Title:	President and CEO	 



 


EXECUTIVE:


 


	By:	/s/ Thomas H. Moll, Ph.D.	 
	Name:	Thomas H. Moll, Ph.D.	 
	Title:	Vice President of Research	 



 



    	 



    	 	



    



 


EXHIBIT A


 


RELEASE AND WAIVER OF CLAIMS


 


In consideration of the severance payments
and other benefits set forth in the Executive Employment Agreement dated as of July 2, 2012 (the “Employment Agreement”),
to which this form is attached, I, Thomas H. Moll, hereby furnish Adamis Pharmaceuticals Corporation (the
“Company”), with the following release and waiver (“Release and Waiver”) and,
intended to be legally bound hereby, agree as follows.


 


In exchange for the consideration provided
to me by the Employment Agreement that I am not otherwise entitled to receive, I hereby generally and completely release the Company
and its directors, officers, Executives, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary
entities, insurers, Affiliates, and assigns from any and all claims, liabilities and obligations, both known and unknown, that
arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to my signing this Release and Waiver.
This general release includes, but is not limited to: (1) all claims arising out of or in any way related to my employment
with the Company or the termination of that employment; (2) all claims related to my compensation or benefits from the Company,
including, but not limited to, salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits,
stock, stock options, or any other ownership interests in the Company; (3) all claims for breach of contract, wrongful termination,
and breach of the implied covenant of good faith and fair dealing; (4) all tort claims, including, but not limited to, claims
for fraud, defamation, emotional distress, and discharge in violation of public policy; and (5) all federal, state, and local
statutory claims, including, but not limited to, claims for discrimination, harassment, retaliation, attorneys’ fees, or
other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990,
the federal Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”), and the California Fair
Employment and Housing Act (as amended). Nothing in this Release and Waiver shall be deemed to require the waiver or release of
any claim that may not be released or waived under applicable federal or state law.


 


I also acknowledge that I have read and
understand Section 1542 of the California Civil Code which reads as follows: “A general release does not extend to
claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if
known by him or her must have materially affected his or her settlement with the debtor.” I hereby expressly waive and
relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to any claims
I may have against the Company.


 


I acknowledge that, among other rights,
I am waiving and releasing any rights I may have under ADEA, that this Release and Waiver is knowing and voluntary, and that the
consideration given for this Release and Waiver is in addition to anything of value to which I was already entitled as an executive
of the Company. I further acknowledge that I have been advised, as required by the Older Workers Benefit Protection Act, that:
(a) the release and waiver granted herein does not relate to claims under the ADEA which may arise after this Release and
Waiver is executed; (b) I should consult with an attorney prior to executing this Release and Waiver;


 



    	A-1



    	 



    
 


(c) I have twenty-one (21) days
from the date of termination of my employment with the Company in which to consider this Release and Waiver (although I may choose
voluntarily to execute this Release and Waiver earlier); (d) I have seven (7) days following the execution of this Release
and Waiver to revoke my consent to this Release and Waiver; and (e) this Release and Waiver shall not be effective until
the seven (7) day revocation period has expired unexercised and no benefits will be paid unless and until this Release and
Waiver has become effective. In the event that this Release and Waiver is requested in connection with an exit incentive or other
employment termination program offered to a group or class of employees, I have forty-five (45) days to consider this Release
and Waiver and I shall be provided with the information required by 29 U.S.C. Section 626 (f)(1)(H).


 


In consideration of the severance payments
and other benefits set forth in the Employment Agreement, I agree that after the termination of my employment with the Company
I will not disparage the Company or its products, services, agents, representatives, directors, officers, shareholders, employees,
affiliates, successors or assigns, or any person acting by, through, under or in concert with any of them with any written or oral
statement. I also agree that during the severance period set forth in the Employment Agreement I will
cooperate from time to time with the Company in providing for the orderly transition of my duties and responsibilities to other
individuals, as reasonably requested by the Company and subject to reimbursement by the Company of any costs or expenses incurred
by me in providing such cooperation. 


 


This Release and Waiver constitutes
the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter
hereof. I am not relying on any promise or representation by the Company that is not expressly stated herein. This Release and
Waiver may only be modified by a writing signed by both me and a duly authorized member of the Board of Directors of the Company. 


 


 


	Date: ________, 20__		/s/ Thomas H. Moll
	 	 	Thomas
H. Moll




 



    	A-2